Close Menu

NEW YORK (360Dx) – The US Food and Drug Administration has given Guardant Health an investigational device exemption approval to provide genomic testing for a cancer drug currently under development.

Guardant is providing testing for a clinical trial of the small molecule, c-Met kinase inhibitor called tepotinib being developed by Merck KGaA, which operates as EMD Serono in the US and Canada. Merck is using Guardant's liquid biopsy test Guardant360 CDx to identify patients with Met exon 14 skipping alterations who may qualify for the ongoing Phase II tepotinib trial.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Kelvin Droegemeier, the director of the White House Office of Science and Technology Policy, is the new acting director of the US National Science Foundation.

An opinion piece at the Guardian discusses the state of SARS-CoV-2 testing in the UK.

Wired reports the University of California, Berkeley's Innovative Genomics Institute has transformed itself into a diagnostic lab to run SARS-CoV-2 tests.

In Nature this week: direct-capture Perturb-seq approach for combinatorial single-cell CRISPR screens, potential uses of genome-editing in breeding crops, and more.